Non-APOE4 carriers do not benefit from treatment with lecanemab, which reduces the rate of progression of APOE4 carriers. Read more here.

High-dose supplements of docosahexaenoic acid (DHA), an omega-3 fatty acid, penetrated the brain in both APOE4 carriers and non-carriers before dementia onset, the placebo-controlled PreventE4 ...

Anti-amyloid drugs only modestly slow down the progression of Alzheimer's in APOE4 carriers and have no effect on non-carriers. Read what it means for Eli Lilly.

The study reveals that APOE4, a genetic risk factor for Alzheimer's Disease and cardiovascular diseases, has complex effects on mortality risk. While APOE4 carriers with higher AD neuropathology ...

Could early signs of Alzheimer’s disease be found in the brain’s vascular defenses? New research published in Alzheimer’s & ...

Early, Sustained and Statistically Significant Reduction in Plasma P-tau 181 Reaching 31% at 24 Months Observed in Carriers of One or Two Copies of APOE4 Gene, who Represent Two Thirds of ...

Buntanetap was found to be equally safe in both APOE4 carriers and non-carriers, with no instances of ARIA.

Topline results were announced from a phase 3 trial evaluating valiltramiprosate (ALZ-801) in APOE4 carriers with early Alzheimer disease.

The cerebrospinal fluid of 95 percent of APOE4 homozygotes had signs of amyloid, a hallmark of Alzheimer's, by age 65. There were signs of amyloid in PET scans of 75 percent of APOE4 homozygotes by ...

A study shows that when people have one or two copies of APOE4, myelination is impaired because oligodendrocytes mismanage cholesterol.

"Omega-3s are good for the APOE4 brain when started before dementia symptoms," Yassine told MedPage Today. "This is different in dementia, when APOE4 carriers have a lower increase in brain DHA ...